
David J. Parsley
Examiner (ID: 15367, Phone: (571)272-6890 , Office: P/3643 )
| Most Active Art Unit | 3643 |
| Art Unit(s) | 3643 |
| Total Applications | 2041 |
| Issued Applications | 924 |
| Pending Applications | 184 |
| Abandoned Applications | 965 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19201379
[patent_doc_number] => 20240173278
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => SYSTEMS AND METHODS FOR SUPPLYING NUTRITIONAL SUPPLEMENTS THAT ELIMINATE PERVASIVE ODORS
[patent_app_type] => utility
[patent_app_number] => 18/059142
[patent_app_country] => US
[patent_app_date] => 2022-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4696
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059142
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/059142 | SYSTEMS AND METHODS FOR SUPPLYING NUTRITIONAL SUPPLEMENTS THAT ELIMINATE PERVASIVE ODORS | Nov 27, 2022 | Pending |
Array
(
[id] => 18360453
[patent_doc_number] => 20230142044
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => METHOD OF PROVIDING CELIPROLOL THERAPY TO A PATIENT
[patent_app_type] => utility
[patent_app_number] => 17/985627
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17985627
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/985627 | METHOD OF PROVIDING CELIPROLOL THERAPY TO A PATIENT | Nov 10, 2022 | Abandoned |
Array
(
[id] => 18312620
[patent_doc_number] => 20230116520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => CO-CRYSTALS
[patent_app_type] => utility
[patent_app_number] => 17/973297
[patent_app_country] => US
[patent_app_date] => 2022-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34137
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17973297
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/973297 | Co-crystals | Oct 24, 2022 | Issued |
Array
(
[id] => 18107907
[patent_doc_number] => 20230000787
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders
[patent_app_type] => utility
[patent_app_number] => 17/930709
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20163
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930709
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930709 | Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders | Sep 7, 2022 | Abandoned |
Array
(
[id] => 18284986
[patent_doc_number] => 20230100458
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/897116
[patent_app_country] => US
[patent_app_date] => 2022-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16801
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17897116
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/897116 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | Aug 25, 2022 | Abandoned |
Array
(
[id] => 19032462
[patent_doc_number] => 20240082277
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => MODIFIED ANTIHISTAMINE COMPOSITION AND ANTIVIRAL TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/890816
[patent_app_country] => US
[patent_app_date] => 2022-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3358
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17890816
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/890816 | MODIFIED ANTIHISTAMINE COMPOSITION AND ANTIVIRAL TREATMENT | Aug 17, 2022 | Abandoned |
Array
(
[id] => 20171707
[patent_doc_number] => 12390427
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-19
[patent_title] => Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
[patent_app_type] => utility
[patent_app_number] => 17/883245
[patent_app_country] => US
[patent_app_date] => 2022-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 21
[patent_no_of_words] => 4685
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17883245
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/883245 | Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use | Aug 7, 2022 | Issued |
Array
(
[id] => 19104611
[patent_doc_number] => 11957684
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Treatment of heavy menstrual bleeding associated with uterine fibroids
[patent_app_type] => utility
[patent_app_number] => 17/866201
[patent_app_country] => US
[patent_app_date] => 2022-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 224
[patent_figures_cnt] => 262
[patent_no_of_words] => 112490
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866201
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/866201 | Treatment of heavy menstrual bleeding associated with uterine fibroids | Jul 14, 2022 | Issued |
Array
(
[id] => 19104611
[patent_doc_number] => 11957684
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Treatment of heavy menstrual bleeding associated with uterine fibroids
[patent_app_type] => utility
[patent_app_number] => 17/866201
[patent_app_country] => US
[patent_app_date] => 2022-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 224
[patent_figures_cnt] => 262
[patent_no_of_words] => 112490
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866201
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/866201 | Treatment of heavy menstrual bleeding associated with uterine fibroids | Jul 14, 2022 | Issued |
Array
(
[id] => 19104611
[patent_doc_number] => 11957684
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Treatment of heavy menstrual bleeding associated with uterine fibroids
[patent_app_type] => utility
[patent_app_number] => 17/866201
[patent_app_country] => US
[patent_app_date] => 2022-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 224
[patent_figures_cnt] => 262
[patent_no_of_words] => 112490
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866201
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/866201 | Treatment of heavy menstrual bleeding associated with uterine fibroids | Jul 14, 2022 | Issued |
Array
(
[id] => 19104611
[patent_doc_number] => 11957684
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Treatment of heavy menstrual bleeding associated with uterine fibroids
[patent_app_type] => utility
[patent_app_number] => 17/866201
[patent_app_country] => US
[patent_app_date] => 2022-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 224
[patent_figures_cnt] => 262
[patent_no_of_words] => 112490
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866201
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/866201 | Treatment of heavy menstrual bleeding associated with uterine fibroids | Jul 14, 2022 | Issued |
Array
(
[id] => 19497570
[patent_doc_number] => 20240336588
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS
[patent_app_type] => utility
[patent_app_number] => 18/576176
[patent_app_country] => US
[patent_app_date] => 2022-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18576176
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/576176 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | Jul 13, 2022 | Pending |
Array
(
[id] => 19360783
[patent_doc_number] => 20240262817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2
[patent_app_type] => utility
[patent_app_number] => 18/560558
[patent_app_country] => US
[patent_app_date] => 2022-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18573
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18560558
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/560558 | QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 | Jul 12, 2022 | Pending |
Array
(
[id] => 18003431
[patent_doc_number] => 20220362197
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => LIPIDS WITH ODD NUMBER OF CARBON ATOMS AND THEIR USE AS PHARMACEUTICAL COMPOSITION OR NUTRITIONAL SUPPLEMENT
[patent_app_type] => utility
[patent_app_number] => 17/810044
[patent_app_country] => US
[patent_app_date] => 2022-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23047
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810044
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/810044 | LIPIDS WITH ODD NUMBER OF CARBON ATOMS AND THEIR USE AS PHARMACEUTICAL COMPOSITION OR NUTRITIONAL SUPPLEMENT | Jun 29, 2022 | Pending |
Array
(
[id] => 17944288
[patent_doc_number] => 20220331305
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => Pharmaceutical Compositions Comprising Alpelisib
[patent_app_type] => utility
[patent_app_number] => 17/853537
[patent_app_country] => US
[patent_app_date] => 2022-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11407
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853537
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/853537 | Pharmaceutical Compositions Comprising Alpelisib | Jun 28, 2022 | Pending |
Array
(
[id] => 17928333
[patent_doc_number] => 20220323458
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => SUSTAINED RELEASE OLANZAPINE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 17/847685
[patent_app_country] => US
[patent_app_date] => 2022-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8598
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847685
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/847685 | SUSTAINED RELEASE OLANZAPINE FORMULATIONS | Jun 22, 2022 | Abandoned |
Array
(
[id] => 19667418
[patent_doc_number] => 12180145
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-31
[patent_title] => Fused cyclooctyne compounds and their use in metal-free click reactions
[patent_app_type] => utility
[patent_app_number] => 17/839202
[patent_app_country] => US
[patent_app_date] => 2022-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 11584
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 645
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17839202
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/839202 | Fused cyclooctyne compounds and their use in metal-free click reactions | Jun 12, 2022 | Issued |
Array
(
[id] => 19343494
[patent_doc_number] => 20240252457
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => Treatment or Prevention of Ischaemia Reperfusion Injury
[patent_app_type] => utility
[patent_app_number] => 18/568243
[patent_app_country] => US
[patent_app_date] => 2022-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12054
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568243
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/568243 | Treatment or Prevention of Ischaemia Reperfusion Injury | Jun 7, 2022 | Pending |
Array
(
[id] => 19402112
[patent_doc_number] => 20240285623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/567877
[patent_app_country] => US
[patent_app_date] => 2022-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8973
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18567877
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/567877 | TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES | Jun 6, 2022 | Pending |
Array
(
[id] => 19387800
[patent_doc_number] => 20240277670
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => SAFE USE OF MMP-12 INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/568043
[patent_app_country] => US
[patent_app_date] => 2022-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12805
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568043
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/568043 | SAFE USE OF MMP-12 INHIBITOR | Jun 6, 2022 | Pending |